BEACH J:
1 As I said in my reasons concerning the first court hearing (Healthscope Limited, in the matter of Healthscope Limited [2019] FCA 542), Healthscope Limited is a healthcare provider that operates private hospitals in Australia and pathology services across New Zealand and whose shares are currently listed on the ASX.
2 Healthscope has now applied for orders under s 411(4)(b) of the Corporations Act 2001 (Cth) (the Act) approving a scheme of arrangement (the Scheme) proposed to be made between Healthscope and its shareholders at the relevant record date (Scheme shareholders). ASIC has been given the required notice of the present hearing. As I have indicated previously, the Scheme will result in all shares in Healthscope held by Scheme shareholders being transferred to Brookfield BidCo. Brookfield BidCo is indirectly owned as to 99% by Brookfield LP and as to 1% by Brookfield Capital Partners V (CDN II) GP LP. Terminology in the present reasons will use the defined terms from my earlier reasons.
3 At the Scheme meeting on 22 May 2019, the resolution to agree to the Scheme was passed by 96.59% of shareholders present and voting in person or by proxy and 99.93% of votes cast.
4 The Scheme consideration is a cash payment of $2.465 per Scheme share. However, the Scheme provides for Scheme shareholders to make an election to receive scrip rather than cash in certain circumstances in the form of 2.465 class B shares in Brookfield HoldCo for every Scheme share held. But any entitlement to the Scheme scrip consideration is subject to a number of conditions, including that valid elections to receive the Scheme scrip consideration are made by Scheme shareholders holding in aggregate at least 10% of the issued Scheme shares. Now the evidence before me suggests that this condition is unlikely to be satisfied. In particular, Healthscope received elections from Scheme shareholders representing less than 0.01% of the Scheme shares in aggregate before the scrip election deadline, which was 10 May 2019. Accordingly, present indications are that the 10% minimum will not be satisfied by the Scheme record date of 30 May 2019, so the Scheme consideration will be cash only.
5 Now in case the Scheme was not agreed to by the Scheme shareholders, Brookfield LP also made a simultaneous off-market takeover offer to acquire all of the issued Healthscope shares for cash payments totalling $2.365 per share. But as Scheme shareholders have agreed to the Scheme, the takeover bid will not proceed unless I refuse to approve the Scheme.
6 Let me say something about my power to approve the Scheme under s 411(4)(b). In essence, my role at the second court hearing is to assess the Scheme taking into account the "totality of the give and take that is the compromise or arrangement" and to determine on that basis whether the Scheme is fair and reasonable (Re Boart Longyear Ltd (No 2) (2017) 323 FLR 241 at [56] per Black J). Of course, the Court can only approve a scheme of arrangement if the requisite majority of shareholders vote in favour of it, but I am not bound to approve the Scheme simply because I previously made orders for the convening of a Scheme meeting and subsequently the requisite majority of shareholders agreed to it. But I accept that shareholders voting collectively at the Scheme meeting are better judges of what is to their commercial advantage and in their interests than the Court and accordingly, absent good reason, I should give effect to their intentions.
7 Now whilst there is no exhaustive statement of the matters as to which I must be satisfied before granting approval, it is not in doubt that in exercising my power under s 411(4)(b), I should be satisfied that:
(a) the Scheme complies with the law, including the relevant procedural requirements;
(b) the Scheme was approved by shareholders acting in good faith and for proper purposes;
(c) the Scheme is sufficiently fair and reasonable that an intelligent and honest shareholder properly informed and acting alone might approve it;
(d) there has been an accurate and comprehensive disclosure of the details of the Scheme and its effect to those voting on it;
(e) there is no suggestion of oppression of any minority;
(f) there is no evidence that any third parties will be adversely affected by the operation of the Scheme;
(g) the Scheme does not offend against any aspect of public policy; and
(h) all matters that could be considered relevant to the exercise of my discretion have been brought to my attention.
8 I also need to be satisfied that the conditions precedent to the Scheme have been met, and that ASIC has been given the opportunity to draw my attention to any relevant matter(s). I would say now that I am so satisfied concerning the conditions precedent. Moreover, ASIC has had adequate opportunity to draw any necessary matters to my attention. I will discuss any relevant Chapter 6 question and s 411(17) later.
9 More particularly in considering whether the Scheme complies with the law, including the relevant procedural requirements, I need to satisfy myself that the procedural and other requirements in the Act, Corporations Regulations 2001 (Cth) and Federal Court (Corporations) Rules 2000 (Cth) have been complied with and that the requirements for a valid resolution of the shareholders have been satisfied. I am so satisfied, including as to any relevant class question which I disposed of on the last occasion.
10 In particular, I am satisfied that the Scheme materials have been properly despatched in accordance with my orders at the first hearing, the resolution agreeing to the Scheme has been passed by the statutory majorities required by s 411(4)(a), and ASIC as I say has been given an opportunity to consider the Scheme pursuant to s 411(17).
11 Now as I have said, my task is to consider whether the Scheme is fair and reasonable and the test of fairness and reasonableness is whether "an intelligent and honest [shareholder], properly informed, acting alone, might approve [the scheme]" (Fowler v Lindholm (2009) 178 FCR 563 at [79] per Emmett, Gordon and Jagot JJ).
12 But the Scheme shareholders' vote in favour of the Scheme is evidence of its inherent fairness. Put another way, if a majority of the Scheme shareholders have approved the Scheme, it is unlikely that the Scheme would be unreasonable. Further, I do not have to be satisfied that no better Scheme could have been devised.
13 Further, I have to be satisfied that "the minority is not being overridden by a majority having interests of its own clashing with those of the minority whom they seek to coerce" (In re Alabama, New Orleans, Texas and Pacific Junction Railway Company [1891] 1 Ch 213 at 239 per Lindley LJ, applied in Re Boart Longyear Ltd (No 2) (2017) 323 FLR 241 at [57] per Black J).
14 Further, it is also appropriate to look more broadly and to consider the indirect consequences of approving the Scheme, the effects of the Scheme on any third parties and matters of public policy.
15 In summary, in my view the Scheme should be approved for the following reasons.
16 First, as I have said, the Scheme shareholders voted overwhelmingly in favour of the Scheme at the Scheme meeting held on 22 May 2019.
17 Further, voter turnout at the Scheme meeting was reasonable. It would seem that 62.17% of all shares were voted either 'For' or 'Against' the Scheme resolution or were the subject of an abstain instruction for voting on the Scheme resolution compared with the total number of shares (1,741,161,795) eligible to be voted, and 16.96% of shareholders voted either 'For' or 'Against' the Scheme resolution or provided an abstain instruction for voting on the Scheme resolution compared with the total number of shareholders (21,595) eligible to vote. The authorities relating to the approval of a scheme where there has been low voter turnout at the scheme meeting are not particularly relevant to this matter. But in any event, the comments of Santow J in Re Matine Ltd (1998) 28 ACSR 268 at 295 that "[t]he apathetic shareholder who chooses not to vote upon a scheme should not be presumed to be antagonistic to the scheme or to warrant paternalistic protection" are apposite.
18 Second, there is no suggestion of any bad faith motivation or improper purpose in relation to the Scheme concerning either how it has been propounded or voted on.
19 Third, the outcome of the Scheme meeting is prima facie evidence that the Scheme is fair and reasonable, and I am satisfied based on its outcome that an intelligent and honest shareholder, properly informed and acting alone, would approve of the Scheme. Moreover, the fairness and reasonableness of the Scheme is supported by the report of the independent expert, Grant Samuel.
20 Fourth, all matters of potential relevance to the approval of the Scheme would seem to have been drawn to my attention and, through the transaction booklet, disclosed to the Scheme shareholders.
21 Fifth, Healthscope has received no notice that any Scheme shareholder intended to oppose the exercise of my discretion to approve the Scheme. Indeed, no Scheme shareholder attended before me this morning to oppose the approval.
22 Sixth, no minority interests are adversely impacted by the Scheme in any relevant way.
23 It is appropriate to discuss some particular aspects in further detail.